RECORD // Company

Cumberland Pharmaceuticals Inc

Built 2026-11-21T23:59:25Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (6)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Cumberland Pharmaceuticals Inc · Corp enforcement · same registered legal name as 'CUMBERLAND PHARMACEUTICALS INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Cumberland Pharmaceuticals · Ctgov · exact name match to 'CUMBERLAND PHARMACEUTICALS INC' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • CUMBERLAND PHARMACEUTICALS · East licences · exact name match to 'CUMBERLAND PHARMACEUTICALS INC' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • CUMBERLAND PHARMACEUTICALS · East licences · exact name match to 'CUMBERLAND PHARMACEUTICALS INC' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • CUMBERLAND PHARMACEUTICALS INC. · Ny corps · same registered legal name as 'CUMBERLAND PHARMACEUTICALS INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • CUMBERLAND PHARMACEUTICALS INC · USAspending · same registered legal name as 'CUMBERLAND PHARMACEUTICALS INC' Possible match based on name, not a shared identifier. Compare the records. Compare

5 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001087294-26-000079

ItemValuePeriodFormFiledAccessionReport
Revenue$2,156,3563 months ended 2026-09-3010-Q2026-11-130001087294-26-0000792026-11-21 23:59 UTCReport an error
Net income (loss)$77,776,9863 months ended 2026-09-3010-Q2026-11-130001087294-26-0000792026-11-21 23:59 UTCReport an error
Interest expense$4,6043 months ended 2026-09-3010-Q2026-11-130001087294-26-0000792026-11-21 23:59 UTCReport an error
Cash and cash equivalents$80,581,021at 2026-09-3010-Q2026-11-130001087294-26-0000792026-11-21 23:59 UTCReport an error
Contract liabilities, current (from an earlier report)$25,000at 2025-12-3110-K2026-03-090001087294-26-0000202026-11-21 23:59 UTCReport an error

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001087294
Ticker
CPIX
EIN
621765329
Record ID
sx:sec:0001087294

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

17 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 23:59 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-21 23:59 UTCReport an error
State of incorporationTN2026-11-16SEC EDGAR company profile2026-11-21 23:59 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-21 23:59 UTCReport an error
Business address1600 WEST END AVENUE, SUITE 1300, NASHVILLE,, TN, 372032026-11-16SEC EDGAR company profile2026-11-21 23:59 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 23:59 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$44,521,4312025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 23:59 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-2,836,1282025-12-3110-K, XBRL NetIncomeLoss2026-11-21 23:59 UTCReport an error
Total assets (at 2025-12-31)$76,823,9922025-12-3110-K, XBRL Assets2026-11-21 23:59 UTCReport an error
Stockholders' equity (at 2025-12-31)$24,880,3222025-12-3110-K, XBRL StockholdersEquity2026-11-21 23:59 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$11,444,6932025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 23:59 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$4,932,5222025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 23:59 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$97,9032025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 23:59 UTCReport an error
Operating lease liabilities (at 2025-12-31)$4,939,7392025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 23:59 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-10)On November 10, 2026 , Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three and nine months ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. This information is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of…2026-11-10SEC EDGAR 8-K 0001087294-26-000076 (text as filed, excerpt)2026-11-21 23:59 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-26)On October 26, 2026, Cumberland Pharmaceuticals Inc. (the “Company” or “Cumberland”), an innovation-focused biopharmaceutical company developing new products for rare diseases, issued a press release providing an update on its ifetroban product candidate, which is in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD"). A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)…2026-10-26SEC EDGAR 8-K 0001087294-26-000072 (text as filed, excerpt)2026-11-21 23:59 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-26)On October 26, 2026, the Company provided an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with DMD. The Company announced plans to submit a New Drug Application ("NDA") to the U.S. Food and Drug Administration (the “FDA”) for ifetroban as a treatment for the cardiomyopathy associated with DMD. The decision to file the NDA for a Traditional Approval follows a pre-NDA meeting held this fall with the FDA. The planned submission will include data from the Company’s FIGHT DMD™ clinical study and its ongoing open-label extension, data from two natural history databases of DMD patients, preclinical data published in the Journal…2026-10-26SEC EDGAR 8-K 0001087294-26-000072 (text as filed, excerpt)2026-11-21 23:59 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.